<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02127892</url>
  </required_header>
  <id_info>
    <org_study_id>CCI-06-00243</org_study_id>
    <nct_id>NCT02127892</nct_id>
  </id_info>
  <brief_title>SCID Bu/Flu/ATG Study With T Cell Depletion</brief_title>
  <official_title>Phase I/II Trial of Hematopoietic Stem Cell Transplant (HSCT) for Children With Severe Combined Immune Deficiency (SCID) and Without an HLA-Matched Sibling Donor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neena Kapoor, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Children's Hospital Los Angeles</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot clinical trial of hematopoietic stem cell transplantation for patients with a
      diagnosis of Severe Combined Immune Deficiency (SCID) who do not have an HLA-matched sibling
      donor. The stem cells will be derived from a 1) matched unrelated donor (MUD), 2) unrelated
      cord blood donor, or 3) a haplo-identical (parental) donor (in descending order of
      preference).Patients will receive a novel conditioning regimen with Busulfan, Fludarabine and
      Anti-thymocyte globulin (ATG) followed by an unrelated donor hematopoietic stem cell
      transplant (HSCT) with T-cell depletion using the CliniMACS device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is being conducted to assess the following:

        -  overall survival

        -  event-free survival (events are defined as: death,non-engraftment/2nd transplant, immune
           reconstitution failure)

        -  acute toxicity of the conditioning regimen

        -  engraftment frequency immune reconstitution frequency and tempo acute and chronic
           graft-versus-host disease (GVHD), frequency and severity.

      The outcome from this protocol will be compared to the retrospective cohort consisting of all
      patients who have undergone haplo-identical HSCT for SCID at CHLA from 1984-2006 based on the
      assessment of the above-listed endpoints.

      The CliniMACS device will be used for CD34+ selection in place of the Isolex 300i. The
      CliniMACS CD34 Reagent System is an investigational medical device that has not yet been
      approved by the FDA. This device is used in vitro to select and enrich specific cell
      populations. When using the CliniMACS CD34 Reagent, the system selects CD34+ cells from
      heterogenous hematological cell populations for transplantation in cases where this is
      clinically indicated.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Closed due to slow accrual. Nine subjects enrolled over 7 years.
  </why_stopped>
  <start_date type="Actual">January 2, 2007</start_date>
  <completion_date type="Actual">August 1, 2016</completion_date>
  <primary_completion_date type="Actual">August 1, 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Engraftment</measure>
    <time_frame>100 day</time_frame>
    <description>Engraftment is defined as recovery of blood counts (neutrophil and platelet engraftment) with cells of donor origin, documented by either bone marrow or peripheral blood chimerism assays after hematopoietic stem cell transplant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Donor-derived CD3+ T Lymphocytes &gt;/= 100/mm3</measure>
    <time_frame>1 year</time_frame>
    <description>Absolute number of donor-derived CD3+ T lymphocytes &gt;/= 100/mm3 in participating subjects.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of Participants With Veno-occlusive Disease (VOD) - Moderate and Severe</measure>
    <time_frame>100 days</time_frame>
    <description>Evaluation of veno-occlusive disease determined by the presence of the following features; fluid retention, weight gain, leaky capillary syndrome, painful liver enlargement, refractoriness to platelet tranfusion and hyperbilirubinemia</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of Participants With Graft Versus Host Disease (GVHD) - Grade III or IV</measure>
    <time_frame>1 year</time_frame>
    <description>GVHD disease surveillance done by clinical evaluation, to include history, physical examination, specifically for rash, jaundice, liver dysfunction, nausea and vomiting, diarrhea and failure to thrive.</description>
  </other_outcome>
  <other_outcome>
    <measure>Overall Survival</measure>
    <time_frame>1 year</time_frame>
    <description>Overalls survival of patient at 1 year post transplant</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Severe Combined Immunodeficiency</condition>
  <arm_group>
    <arm_group_label>unrelated BM with T cell depletion</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Acceptable matching for matched unrelated donor (MUD) bone marrow will be genotypic matches at 10 of 10 HLA alleles (HLA-A, B, C, DR and DQ) or 9 of 10 HLA alleles.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>unrelated cord blood</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Acceptable matching for unrelated cord blood will be a genotypic match at 6 of 6 alleles (HLA A, B and DR) or 5 of 6 alleles, but not with mismatches at both alleles of a single locus (e.g. not mismatched for both HLA A alleles).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>haplo BM with T cell depletion</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>If there is no unrelated donor available meeting the matching criteria for unrelated bone marrow or unrelated cord blood donors.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>unrelated PBSC with T cell depletion</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The preferred source will be bone marrow, however, if a donor is unable or unwilling to donate bone marrow, peripheral blood stem cells (PBSC) will be allowed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>unrelated BM with T cell depletion</intervention_name>
    <description>Remaining unmanipulated bone marrow will be processed to isolate CD34+ cells (T cell depleted).</description>
    <arm_group_label>unrelated BM with T cell depletion</arm_group_label>
    <other_name>CD34+ selection using CliniMACS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>unrelated cord blood</intervention_name>
    <description>Cord blood will be thawed (and processed if ABO incompatibility) per institutional SOP.</description>
    <arm_group_label>unrelated cord blood</arm_group_label>
    <other_name>umbilical cord blood</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>haplo BM with T cell depletion</intervention_name>
    <description>haplo-identical (parental) bone marrow will be processed for CD34+ cell isolation.</description>
    <arm_group_label>haplo BM with T cell depletion</arm_group_label>
    <other_name>CD34+ selection with CliniMACS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>unrelated PBSC with T cell depletion</intervention_name>
    <description>peripheral blood stem cell will be processed for CD34+ cell isolation.</description>
    <arm_group_label>unrelated PBSC with T cell depletion</arm_group_label>
    <other_name>CD34+ selection using CliniMACS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients with SCID who lack a histocompatible sibling or HLA-matched related donor
             will be considered as candidates for this study protocol.

          -  Eligible patients must have adequate physical function to tolerate the chemotherapy
             conditioning regimen and the HSCT, as measure by:

               1. Renal: creatinine clearance or GFR â‰¥50 ml/min/1.73m2, and not requiring dialysis

               2. Pulmonary: Because patients with SCID frequently present with infectious
                  pneumonia causing ventilatory failure, patients will be considered for enrollment
                  in the study even if respiratory failure requiring mechanical ventilatory support
                  is present. In patients recently diagnosed with pneumonia, efforts to stabilize
                  the respiratory status will be made prior to enrollment in the study.

               3. Infectious disease status. The presence of infection per se will not be a reason
                  for exclusion from the study. Patients with SCID are frequently infected with
                  both routine pathogens as well as opportunistic infections. Antibiotic,
                  antifungal and antiviral prophylaxis and therapy will be instituted as clinically
                  indicated. Despite the use of antimicrobial therapy, the ability to control
                  infections will not be achieved unless HSCT is performed. Therefore, subjects may
                  be enrolled in the study, even though infection is present, because control of
                  infection may depend on engraftment of a donor immune system.

               4. Patients will be 0-21 years of age.

        Exclusion Criteria:

          -  Patient with histocompatible sibling or other related donor

          -  End-organ failure that precludes the ability to tolerate the transplant procedure,
             including conditioning.

          -  Renal failure requiring dialysis

          -  Congenital heart disease resulting in congestive heart failure

          -  Severe CNS disease, e.g., coma or intractable seizures

          -  Ventilatory failure due to non-infectious etiology

          -  Major congenital anomalies that adversely affect survival, eg CNS malformations

          -  Metabolic diseases that would affect transplant survival, eg urea cycle disorders

          -  HIV infection

        Since the only chance of survival for patients with SCID is successful transplantation, all
        patients with SCID will be considered to be potential subjects for the study, regardless of
        end-organ dysfunction.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neena Kapoor, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Children's Hospital Los Angeles, University of Southern California</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2012</study_first_submitted>
  <study_first_submitted_qc>April 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2014</study_first_posted>
  <results_first_submitted>July 17, 2017</results_first_submitted>
  <results_first_submitted_qc>August 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 18, 2017</results_first_posted>
  <last_update_submitted>August 18, 2017</last_update_submitted>
  <last_update_submitted_qc>August 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Children's Hospital Los Angeles</investigator_affiliation>
    <investigator_full_name>Neena Kapoor, M.D.</investigator_full_name>
    <investigator_title>Professor of Pediatrics, Keck School of Medicine; Division Head, Division of Research Immunology/BMT</investigator_title>
  </responsible_party>
  <keyword>Severe Combined Immune Deficiency</keyword>
  <keyword>SCID</keyword>
  <keyword>HLA-matched unrelated donor</keyword>
  <keyword>unrelated</keyword>
  <keyword>MUD</keyword>
  <keyword>bone marrow</keyword>
  <keyword>cord blood</keyword>
  <keyword>haplo-identical</keyword>
  <keyword>peripheral blood</keyword>
  <keyword>CD34+ selection</keyword>
  <keyword>T cell depletion</keyword>
  <keyword>HSCT</keyword>
  <keyword>BMT</keyword>
  <keyword>CliniMACS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Severe Combined Immunodeficiency</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Unrelated BM With T Cell Depletion</title>
          <description>Acceptable matching for matched unrelated donor (MUD) bone marrow will be genotypic matches at 10 of 10 HLA alleles (HLA-A, B, C, DR and DQ) or 9 of 10 HLA alleles.
unrelated BM with T cell depletion: Remaining unmanipulated bone marrow will be processed to isolate CD34+ cells (T cell depleted).</description>
        </group>
        <group group_id="P2">
          <title>Unrelated Cord Blood</title>
          <description>Acceptable matching for unrelated cord blood will be a genotypic match at 6 of 6 alleles (HLA A, B and DR) or 5 of 6 alleles, but not with mismatches at both alleles of a single locus (e.g. not mismatched for both HLA A alleles).
unrelated cord blood: Cord blood will be thawed (and processed if ABO incompatibility) per institutional SOP.</description>
        </group>
        <group group_id="P3">
          <title>Haplo BM With T Cell Depletion</title>
          <description>If there is no unrelated donor available meeting the matching criteria for unrelated bone marrow or unrelated cord blood donors.
haplo BM with T cell depletion: haplo-identical (parental) bone marrow will be processed for CD34+ cell isolation.</description>
        </group>
        <group group_id="P4">
          <title>Unrelated PBSC With T Cell Depletion</title>
          <description>The preferred source will be bone marrow, however, if a donor is unable or unwilling to donate bone marrow, peripheral blood stem cells (PBSC) will be allowed.
unrelated PBSC with T cell depletion: peripheral blood stem cell will be processed for CD34+ cell isolation.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Unrelated BM With T Cell Depletion</title>
          <description>Acceptable matching for matched unrelated donor (MUD) bone marrow will be genotypic matches at 10 of 10 HLA alleles (HLA-A, B, C, DR and DQ) or 9 of 10 HLA alleles.
unrelated BM with T cell depletion: Remaining unmanipulated bone marrow will be processed to isolate CD34+ cells (T cell depleted).</description>
        </group>
        <group group_id="B2">
          <title>Unrelated Cord Blood</title>
          <description>Acceptable matching for unrelated cord blood will be a genotypic match at 6 of 6 alleles (HLA A, B and DR) or 5 of 6 alleles, but not with mismatches at both alleles of a single locus (e.g. not mismatched for both HLA A alleles).
unrelated cord blood: Cord blood will be thawed (and processed if ABO incompatibility) per institutional SOP.</description>
        </group>
        <group group_id="B3">
          <title>Haplo BM With T Cell Depletion</title>
          <description>If there is no unrelated donor available meeting the matching criteria for unrelated bone marrow or unrelated cord blood donors.
haplo BM with T cell depletion: haplo-identical (parental) bone marrow will be processed for CD34+ cell isolation.</description>
        </group>
        <group group_id="B4">
          <title>Unrelated PBSC With T Cell Depletion</title>
          <description>The preferred source will be bone marrow, however, if a donor is unable or unwilling to donate bone marrow, peripheral blood stem cells (PBSC) will be allowed.
unrelated PBSC with T cell depletion: peripheral blood stem cell will be processed for CD34+ cell isolation.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="0"/>
            <count group_id="B4" value="0"/>
            <count group_id="B5" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B5" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Engraftment</title>
        <description>Engraftment is defined as recovery of blood counts (neutrophil and platelet engraftment) with cells of donor origin, documented by either bone marrow or peripheral blood chimerism assays after hematopoietic stem cell transplant.</description>
        <time_frame>100 day</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unrelated BM With T Cell Depletion</title>
            <description>Acceptable matching for matched unrelated donor (MUD) bone marrow will be genotypic matches at 10 of 10 HLA alleles (HLA-A, B, C, DR and DQ) or 9 of 10 HLA alleles.
unrelated BM with T cell depletion: Remaining unmanipulated bone marrow will be processed to isolate CD34+ cells (T cell depleted).</description>
          </group>
          <group group_id="O2">
            <title>Unrelated Cord Blood</title>
            <description>Acceptable matching for unrelated cord blood will be a genotypic match at 6 of 6 alleles (HLA A, B and DR) or 5 of 6 alleles, but not with mismatches at both alleles of a single locus (e.g. not mismatched for both HLA A alleles).
unrelated cord blood: Cord blood will be thawed (and processed if ABO incompatibility) per institutional SOP.</description>
          </group>
          <group group_id="O3">
            <title>Haplo BM With T Cell Depletion</title>
            <description>If there is no unrelated donor available meeting the matching criteria for unrelated bone marrow or unrelated cord blood donors.
haplo BM with T cell depletion: haplo-identical (parental) bone marrow will be processed for CD34+ cell isolation.</description>
          </group>
          <group group_id="O4">
            <title>Unrelated PBSC With T Cell Depletion</title>
            <description>The preferred source will be bone marrow, however, if a donor is unable or unwilling to donate bone marrow, peripheral blood stem cells (PBSC) will be allowed.
unrelated PBSC with T cell depletion: peripheral blood stem cell will be processed for CD34+ cell isolation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Engraftment</title>
          <description>Engraftment is defined as recovery of blood counts (neutrophil and platelet engraftment) with cells of donor origin, documented by either bone marrow or peripheral blood chimerism assays after hematopoietic stem cell transplant.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Donor-derived CD3+ T Lymphocytes &gt;/= 100/mm3</title>
        <description>Absolute number of donor-derived CD3+ T lymphocytes &gt;/= 100/mm3 in participating subjects.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unrelated BM With T Cell Depletion</title>
            <description>Acceptable matching for matched unrelated donor (MUD) bone marrow will be genotypic matches at 10 of 10 HLA alleles (HLA-A, B, C, DR and DQ) or 9 of 10 HLA alleles.
unrelated BM with T cell depletion: Remaining unmanipulated bone marrow will be processed to isolate CD34+ cells (T cell depleted).</description>
          </group>
          <group group_id="O2">
            <title>Unrelated Cord Blood</title>
            <description>Acceptable matching for unrelated cord blood will be a genotypic match at 6 of 6 alleles (HLA A, B and DR) or 5 of 6 alleles, but not with mismatches at both alleles of a single locus (e.g. not mismatched for both HLA A alleles).
unrelated cord blood: Cord blood will be thawed (and processed if ABO incompatibility) per institutional SOP.</description>
          </group>
          <group group_id="O3">
            <title>Haplo BM With T Cell Depletion</title>
            <description>If there is no unrelated donor available meeting the matching criteria for unrelated bone marrow or unrelated cord blood donors.
haplo BM with T cell depletion: haplo-identical (parental) bone marrow will be processed for CD34+ cell isolation.</description>
          </group>
          <group group_id="O4">
            <title>Unrelated PBSC With T Cell Depletion</title>
            <description>The preferred source will be bone marrow, however, if a donor is unable or unwilling to donate bone marrow, peripheral blood stem cells (PBSC) will be allowed.
unrelated PBSC with T cell depletion: peripheral blood stem cell will be processed for CD34+ cell isolation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Donor-derived CD3+ T Lymphocytes &gt;/= 100/mm3</title>
          <description>Absolute number of donor-derived CD3+ T lymphocytes &gt;/= 100/mm3 in participating subjects.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Veno-occlusive Disease (VOD) - Moderate and Severe</title>
        <description>Evaluation of veno-occlusive disease determined by the presence of the following features; fluid retention, weight gain, leaky capillary syndrome, painful liver enlargement, refractoriness to platelet tranfusion and hyperbilirubinemia</description>
        <time_frame>100 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unrelated BM With T Cell Depletion</title>
            <description>Acceptable matching for matched unrelated donor (MUD) bone marrow will be genotypic matches at 10 of 10 HLA alleles (HLA-A, B, C, DR and DQ) or 9 of 10 HLA alleles.
unrelated BM with T cell depletion: Remaining unmanipulated bone marrow will be processed to isolate CD34+ cells (T cell depleted).</description>
          </group>
          <group group_id="O2">
            <title>Unrelated Cord Blood</title>
            <description>Acceptable matching for unrelated cord blood will be a genotypic match at 6 of 6 alleles (HLA A, B and DR) or 5 of 6 alleles, but not with mismatches at both alleles of a single locus (e.g. not mismatched for both HLA A alleles).
unrelated cord blood: Cord blood will be thawed (and processed if ABO incompatibility) per institutional SOP.</description>
          </group>
          <group group_id="O3">
            <title>Haplo BM With T Cell Depletion</title>
            <description>If there is no unrelated donor available meeting the matching criteria for unrelated bone marrow or unrelated cord blood donors.
haplo BM with T cell depletion: haplo-identical (parental) bone marrow will be processed for CD34+ cell isolation.</description>
          </group>
          <group group_id="O4">
            <title>Unrelated PBSC With T Cell Depletion</title>
            <description>The preferred source will be bone marrow, however, if a donor is unable or unwilling to donate bone marrow, peripheral blood stem cells (PBSC) will be allowed.
unrelated PBSC with T cell depletion: peripheral blood stem cell will be processed for CD34+ cell isolation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Veno-occlusive Disease (VOD) - Moderate and Severe</title>
          <description>Evaluation of veno-occlusive disease determined by the presence of the following features; fluid retention, weight gain, leaky capillary syndrome, painful liver enlargement, refractoriness to platelet tranfusion and hyperbilirubinemia</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Participants With Graft Versus Host Disease (GVHD) - Grade III or IV</title>
        <description>GVHD disease surveillance done by clinical evaluation, to include history, physical examination, specifically for rash, jaundice, liver dysfunction, nausea and vomiting, diarrhea and failure to thrive.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unrelated BM With T Cell Depletion</title>
            <description>Acceptable matching for matched unrelated donor (MUD) bone marrow will be genotypic matches at 10 of 10 HLA alleles (HLA-A, B, C, DR and DQ) or 9 of 10 HLA alleles.
unrelated BM with T cell depletion: Remaining unmanipulated bone marrow will be processed to isolate CD34+ cells (T cell depleted).</description>
          </group>
          <group group_id="O2">
            <title>Unrelated Cord Blood</title>
            <description>Acceptable matching for unrelated cord blood will be a genotypic match at 6 of 6 alleles (HLA A, B and DR) or 5 of 6 alleles, but not with mismatches at both alleles of a single locus (e.g. not mismatched for both HLA A alleles).
unrelated cord blood: Cord blood will be thawed (and processed if ABO incompatibility) per institutional SOP.</description>
          </group>
          <group group_id="O3">
            <title>Haplo BM With T Cell Depletion</title>
            <description>If there is no unrelated donor available meeting the matching criteria for unrelated bone marrow or unrelated cord blood donors.
haplo BM with T cell depletion: haplo-identical (parental) bone marrow will be processed for CD34+ cell isolation.</description>
          </group>
          <group group_id="O4">
            <title>Unrelated PBSC With T Cell Depletion</title>
            <description>The preferred source will be bone marrow, however, if a donor is unable or unwilling to donate bone marrow, peripheral blood stem cells (PBSC) will be allowed.
unrelated PBSC with T cell depletion: peripheral blood stem cell will be processed for CD34+ cell isolation.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Graft Versus Host Disease (GVHD) - Grade III or IV</title>
          <description>GVHD disease surveillance done by clinical evaluation, to include history, physical examination, specifically for rash, jaundice, liver dysfunction, nausea and vomiting, diarrhea and failure to thrive.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Overall Survival</title>
        <description>Overalls survival of patient at 1 year post transplant</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Unrelated BM With T Cell Depletion</title>
            <description>Acceptable matching for matched unrelated donor (MUD) bone marrow will be genotypic matches at 10 of 10 HLA alleles (HLA-A, B, C, DR and DQ) or 9 of 10 HLA alleles.
unrelated BM with T cell depletion: Remaining unmanipulated bone marrow will be processed to isolate CD34+ cells (T cell depleted).</description>
          </group>
          <group group_id="O2">
            <title>Unrelated Cord Blood</title>
            <description>Acceptable matching for unrelated cord blood will be a genotypic match at 6 of 6 alleles (HLA A, B and DR) or 5 of 6 alleles, but not with mismatches at both alleles of a single locus (e.g. not mismatched for both HLA A alleles).
unrelated cord blood: Cord blood will be thawed (and processed if ABO incompatibility) per institutional SOP.</description>
          </group>
          <group group_id="O3">
            <title>Haplo BM With T Cell Depletion</title>
            <description>If there is no unrelated donor available meeting the matching criteria for unrelated bone marrow or unrelated cord blood donors.
haplo BM with T cell depletion: haplo-identical (parental) bone marrow will be processed for CD34+ cell isolation.</description>
          </group>
          <group group_id="O4">
            <title>Unrelated PBSC With T Cell Depletion</title>
            <description>The preferred source will be bone marrow, however, if a donor is unable or unwilling to donate bone marrow, peripheral blood stem cells (PBSC) will be allowed.
unrelated PBSC with T cell depletion: peripheral blood stem cell will be processed for CD34+ cell isolation.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overalls survival of patient at 1 year post transplant</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected over a period of 1 year post transplant.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Unrelated BM With T Cell Depletion</title>
          <description>Acceptable matching for matched unrelated donor (MUD) bone marrow will be genotypic matches at 10 of 10 HLA alleles (HLA-A, B, C, DR and DQ) or 9 of 10 HLA alleles.
unrelated BM with T cell depletion: Remaining unmanipulated bone marrow will be processed to isolate CD34+ cells (T cell depleted).</description>
        </group>
        <group group_id="E2">
          <title>Unrelated Cord Blood</title>
          <description>Acceptable matching for unrelated cord blood will be a genotypic match at 6 of 6 alleles (HLA A, B and DR) or 5 of 6 alleles, but not with mismatches at both alleles of a single locus (e.g. not mismatched for both HLA A alleles).
unrelated cord blood: Cord blood will be thawed (and processed if ABO incompatibility) per institutional SOP.</description>
        </group>
        <group group_id="E3">
          <title>Haplo BM With T Cell Depletion</title>
          <description>If there is no unrelated donor available meeting the matching criteria for unrelated bone marrow or unrelated cord blood donors.
haplo BM with T cell depletion: haplo-identical (parental) bone marrow will be processed for CD34+ cell isolation.</description>
        </group>
        <group group_id="E4">
          <title>Unrelated PBSC With T Cell Depletion</title>
          <description>The preferred source will be bone marrow, however, if a donor is unable or unwilling to donate bone marrow, peripheral blood stem cells (PBSC) will be allowed.
unrelated PBSC with T cell depletion: peripheral blood stem cell will be processed for CD34+ cell isolation.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>SOS</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Sinusoidal obstruction syndrome</sub_title>
                <description>Sinusoidal obstruction syndrome (SOS), previously known as veno-occlusive disease (VOD), is a distinctive and potentially fatal form of hepatic injury that occurs predominantly, if not only, after drug or toxin exposure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection - Aspergillis</sub_title>
                <description>Pulmonary Aspergillis infection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
              <event>
                <sub_title>Infection - Fungal</sub_title>
                <description>Pulmonary fungal infection</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <description>Busulfan toxicity</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Graft Versus Host Disease</sub_title>
                <description>Graft versus host disease - condition post transplant the donor's immune cells in the transplant (graft) make antibodies against the patient's tissues (host) and attack vital organs (skin, GI track and liver common organs attacked)</description>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="0"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Neena Kapoor, M.D.</name_or_title>
      <organization>Children's Hospital Los Angeles</organization>
      <phone>323-361-2546</phone>
      <email>nkapoor@chla.usc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

